UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

As more people receive genetic testing after a cancer diagnosis, newer variants have been identified that increase the risk ...

Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...